JP2001509135A - 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法 - Google Patents

混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法

Info

Publication number
JP2001509135A
JP2001509135A JP51780398A JP51780398A JP2001509135A JP 2001509135 A JP2001509135 A JP 2001509135A JP 51780398 A JP51780398 A JP 51780398A JP 51780398 A JP51780398 A JP 51780398A JP 2001509135 A JP2001509135 A JP 2001509135A
Authority
JP
Japan
Prior art keywords
cells
tumor
human
lymphocytes
allogeneic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51780398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509135A5 (enExample
Inventor
シー． ハイザーロード，ジョン
エイ． トンプソン，ジェイムズ
エイ． グランジャー，ゲイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2001509135A publication Critical patent/JP2001509135A/ja
Publication of JP2001509135A5 publication Critical patent/JP2001509135A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP51780398A 1996-10-11 1997-10-10 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法 Ceased JP2001509135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2854896P 1996-10-11 1996-10-11
US60/028,548 1996-10-11
PCT/US1997/018718 WO1998016238A2 (en) 1996-10-11 1997-10-10 Cancer immunotherapy using tumor cells combined with mixed lymphocytes

Publications (2)

Publication Number Publication Date
JP2001509135A true JP2001509135A (ja) 2001-07-10
JP2001509135A5 JP2001509135A5 (enExample) 2005-06-16

Family

ID=21844058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51780398A Ceased JP2001509135A (ja) 1996-10-11 1997-10-10 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法

Country Status (13)

Country Link
US (1) US6207147B1 (enExample)
EP (1) EP0930887B1 (enExample)
JP (1) JP2001509135A (enExample)
KR (1) KR20000049096A (enExample)
CN (1) CN1237909A (enExample)
AR (1) AR004445A1 (enExample)
AT (1) ATE229810T1 (enExample)
AU (1) AU743855B2 (enExample)
BR (1) BR9712988A (enExample)
CA (1) CA2267157C (enExample)
DE (1) DE69718029T2 (enExample)
NO (1) NO991691L (enExample)
WO (1) WO1998016238A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508018A (ja) * 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
JP2014517830A (ja) * 2011-05-03 2014-07-24 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
AU7154598A (en) * 1997-04-23 1998-11-13 Regents Of The University Of California, The A cell strain with activated anti-cancer cytotoxic activity
DE69837552D1 (de) 1997-10-10 2007-05-24 Univ California Allogene zellkombination enthaltende implantate zur krebsbehandlung
WO1999019462A1 (en) * 1997-10-10 1999-04-22 The Regents Of The University Of California Enhanced immunogenic cell populations prepared using h2 receptor antagonists
DE69820291D1 (de) 1997-10-10 2004-01-15 Meyer Pharmaceuticals Llc Krebsimmuntherapie mittels allostimulierten zellen zur sequentiellen implantationsstrategie
JP4389039B2 (ja) * 1998-04-09 2009-12-24 株式会社リンフォテック アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
EP1159967B1 (en) * 1999-02-09 2008-09-10 Riken Tumor vaccines
US7303911B2 (en) 2000-04-01 2007-12-04 Onyvax Limited Prostate cell lines
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
ATE500808T1 (de) * 2001-05-11 2011-03-15 Wellstat Biologics Corp Onkolytische virustherapie
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
CA2469135A1 (en) * 2001-11-27 2003-06-05 Nexyte Ab Production of eukaryotic proteins and nucleic acid molecules in c. elegans
KR20020060643A (ko) * 2002-06-04 2002-07-18 김진경 타인의 면역시스템을 이용하는 암의 치료 방법
AU2003258090B2 (en) * 2002-08-08 2010-07-22 Baylor College Of Medicine Isolation and identification of T cells
US7571817B2 (en) * 2002-11-06 2009-08-11 Varco I/P, Inc. Automatic separator or shaker with electromagnetic vibrator apparatus
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
EP1641491B1 (en) 2003-06-11 2008-01-02 University of Chicago Increased t-cell tumor infiltration by mutant light
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US20050112684A1 (en) * 2003-11-21 2005-05-26 Eric Holzle Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners
ES2383306T3 (es) 2004-02-03 2012-06-20 The Regents Of The University Of Michigan Composiciones para el tratamiento del cáncer de mama y de páncreas
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
ES2641087T3 (es) 2005-10-31 2017-11-07 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y el tratamiento del cáncer
WO2007053648A2 (en) * 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007100640A2 (en) * 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
ES2553192T3 (es) * 2006-05-05 2015-12-04 Opexa Therapeutics Vacuna de células T
ES2613957T3 (es) 2006-08-04 2017-05-29 Medimmune Limited Anticuerpos contra ERBB2
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2008061392A1 (en) * 2006-11-22 2008-05-29 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008092153A2 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US20090093429A1 (en) * 2007-02-08 2009-04-09 Yang-Xin Fu Combination therapy for treating cancer
EP2650018A3 (en) 2007-05-14 2014-09-03 The University of Chicago Antibody-LIGHT fusion products for cancer therapeutics
CN101855549A (zh) * 2007-09-12 2010-10-06 耶达研究及发展有限公司 在免疫豁免部位内治疗肿瘤的方法
US8114276B2 (en) 2007-10-24 2012-02-14 Baxter International Inc. Personal hemodialysis system
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2779436A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
JP5716180B2 (ja) 2008-11-11 2015-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗ｃｘｃｒ１組成物および方法
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
KR20120093978A (ko) * 2009-10-27 2012-08-23 이뮤니쿰 에이비 항원 특이적 ｔ 세포의 증식 방법
DK2510084T3 (da) * 2009-12-08 2020-04-27 The Board Of Trustees Of The Univ Of Illionis Stamcelleimmunmoduleringsanvendelsesfremgangsmåder og apparat
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20110237461A1 (en) * 2010-03-17 2011-09-29 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
LT3892295T (lt) * 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
US9493532B2 (en) 2011-12-15 2016-11-15 The University Of Chicago Compositions for cancer therapy using mutant light molecules with increased affinity to receptors
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2925104A1 (en) * 2013-09-27 2015-04-02 Vaccinogen International Partners, Lp Autologous tumor vaccines and methods
EP3215165B1 (en) 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
US20180055920A1 (en) * 2015-03-12 2018-03-01 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting cancer
EP3313419B1 (en) * 2015-06-26 2020-08-19 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
CN109068658A (zh) 2015-11-18 2018-12-21 杜克大学 用于治疗癌症的肿瘤浸润淋巴细胞
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US20200237904A1 (en) 2017-01-26 2020-07-30 Immune Therapeutics Inc. Methods and Compositions Useful for Treating Cancer
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
US11446329B2 (en) 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
FR3082730B1 (fr) * 2018-06-21 2022-04-22 Med Inn Pharma Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique
WO2023196232A1 (en) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Method of characterizing tumors
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02150275A (ja) * 1988-11-30 1990-06-08 Jio Res:Kk 免疫記憶細胞懸濁液の調製方法
JPH05509093A (ja) * 1990-07-26 1993-12-16 サノフィ−サンテラボ インターロイキン―７を用いた選定免疫療法
JPH06121672A (ja) * 1992-10-13 1994-05-06 Cellcor Inc 免疫反応性細胞の製造
WO1995003814A1 (en) * 1993-07-30 1995-02-09 Yale University Cellular vaccine and methods of use for the treatment of solid tumor malignancies
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO1996029394A1 (en) * 1995-03-17 1996-09-26 The Regents Of The University Of California Method for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
WO1994020120A1 (en) 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
CA2178950A1 (en) 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
US5759535A (en) 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02150275A (ja) * 1988-11-30 1990-06-08 Jio Res:Kk 免疫記憶細胞懸濁液の調製方法
JPH05509093A (ja) * 1990-07-26 1993-12-16 サノフィ−サンテラボ インターロイキン―７を用いた選定免疫療法
JPH06121672A (ja) * 1992-10-13 1994-05-06 Cellcor Inc 免疫反応性細胞の製造
WO1995003814A1 (en) * 1993-07-30 1995-02-09 Yale University Cellular vaccine and methods of use for the treatment of solid tumor malignancies
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO1996029394A1 (en) * 1995-03-17 1996-09-26 The Regents Of The University Of California Method for treating tumors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508018A (ja) * 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
JP2014517830A (ja) * 2011-05-03 2014-07-24 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
US10350242B2 (en) 2011-05-03 2019-07-16 Immunovative Therapies Ltd. Methods for handling biological drugs containing living cells
US11648273B2 (en) 2011-05-03 2023-05-16 Mirror Biologics, Inc. Methods for handling biological drugs containing living cells

Also Published As

Publication number Publication date
WO1998016238A3 (en) 1998-09-11
CA2267157A1 (en) 1998-04-23
AU743855B2 (en) 2002-02-07
CN1237909A (zh) 1999-12-08
DE69718029T2 (de) 2003-10-16
BR9712988A (pt) 2000-10-24
DE69718029D1 (de) 2003-01-30
US6207147B1 (en) 2001-03-27
ATE229810T1 (de) 2003-01-15
NO991691L (no) 1999-06-09
AU4824297A (en) 1998-05-11
EP0930887B1 (en) 2002-12-18
NO991691D0 (no) 1999-04-09
EP0930887A2 (en) 1999-07-28
AR004445A1 (es) 1998-12-16
WO1998016238A2 (en) 1998-04-23
CA2267157C (en) 2005-05-31
KR20000049096A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
JP2001509135A (ja) 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
US6277368B1 (en) Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
Trefzer et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma
DE69839273T2 (de) Krebsimmuntherapie mit semi-allogenen zellen
Jacobs et al. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes
US6699483B1 (en) Cancer treatments
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
US20080031900A1 (en) Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
Palucka et al. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma
Ashley et al. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo
US20190046568A1 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
Kruse et al. Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors
AU1668300A (en) New cancer treatments
JP2002502880A (ja) ハプテン改変化腫瘍細胞膜およびその使用
US6503503B1 (en) Allogeneic cellular vaccine
US20040022813A1 (en) Shed antigen vaccine with dendritic cells adjuvant
JP2003524583A (ja) 黒色腫患者における肺転移に対して抗腫瘍応答を誘導する方法
JPH09504786A (ja) ハプロタイプ適合サイトカイン分泌細胞および免疫応答を刺激するための使用方法
He et al. Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine
MXPA99003341A (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
Parney Human glioma immunology and immunogene therapy.
Agrawal MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081201

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090526